Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) Stock Soars After the Regulatory Approval of Lymphoaim in India

April 19, 2022

Winning regulatory approval can be a major boost for biopharmaceutical companies and hence, the Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) stock is in action during premarket trading period this morning. Trading Data On Monday, NAVB stock moved up 3% to $0.8860 with more than 79K shares, compared to its average volume of 84K shares. The stock moved within a range of $0.8600 – 0.8999 after opening trade at $0.86. Moreover, the stock…


Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) Stock Reacts Positively After Research Agreement

February 8, 2022

If you are currently looking into the possibility of investing in biopharmaceutical stocks, then it could be the right time to look into the Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) stock. It had emerged as one of the major gainers yesterday and ended up with gains of as much as 24% amidst heavy interest. Trading Data On Monday, NAVB stock soared 23.20% to $0.8870 with more than 1.78 million shares, compared to…